γ-Secretase inhibition promotes fibrotic effects of albumin in proximal tubular epithelial cells

Br J Pharmacol. 2013 Jul;169(6):1239-51. doi: 10.1111/bph.12214.

Abstract

Background and purpose: Albuminuria is an important biomarker of renal dysfunction and is a major mediator of renal damage and fibrosis during kidney disease. The mechanisms underlying albumin-induced renal fibrosis remain unclear. There has been significant interest in γ-secretase activity in tubular epithelial cells in recent times; however, its potential role in albumin-induced fibrosis has not been investigated.

Experimental approach: The primary aim of this study was to examine the role of γ-secretase in albumin-induced fibrotic effects in proximal tubular cells. The effects of increasing albumin concentrations on fibrosis indicators and mediators in the human HK-2 cell line were examined in the presence and absence of a γ-secretase inhibitor, compound E.

Key results: Treatment with albumin resulted in a number of pro-fibrotic effects, including up-regulation of fibronectin, TGF-β1 and the EGF-R. Interestingly, similar effects were observed in response to treatment with the γ-secretase inhibitor, compound E. Co-treatment of cells with albumin and an EGF-R inhibitor, AG-1478, resulted in significant inhibition of the observed pro-fibrotic effects, suggesting a major role for the EGF-R in albumin-induced fibrotic events. Albumin-induced effects on the EGF-R appeared to be mediated through inhibition of γ-secretase activity and were dependent on ERK-MAPK signalling.

Conclusions and implications: These results provide novel insights into the mechanisms of albumin-induced fibrotic effects in tubular epithelial cells, suggesting important roles for the γ-secretase and the EGF-R. These results suggest that the proposed use of γ-secretase inhibitors as anti-fibrotic agents requires further investigation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amyloid Precursor Protein Secretases / antagonists & inhibitors*
  • Amyloid Precursor Protein Secretases / metabolism
  • Animals
  • Benzodiazepinones / pharmacology
  • Cattle
  • Cell Line
  • Culture Media, Serum-Free
  • Endocytosis / drug effects*
  • Enzyme Inhibitors / pharmacology*
  • ErbB Receptors / antagonists & inhibitors
  • ErbB Receptors / metabolism
  • Fibronectins / metabolism
  • Fibrosis
  • Humans
  • Kidney Tubules, Proximal / drug effects*
  • Kidney Tubules, Proximal / metabolism
  • Kidney Tubules, Proximal / pathology
  • MAP Kinase Signaling System / drug effects
  • Opossums
  • Proteolysis / drug effects*
  • Quinazolines / pharmacology
  • Serum Albumin, Bovine / metabolism*
  • Transforming Growth Factor beta1 / metabolism
  • Tyrphostins / pharmacology
  • Urothelium / drug effects*
  • Urothelium / metabolism
  • Urothelium / pathology

Substances

  • 2-(2-(3,5-difluorophenyl)-acetylamino)-N-(1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo(e)(1,4)diazepin-3-yl)propionamide
  • Benzodiazepinones
  • Culture Media, Serum-Free
  • Enzyme Inhibitors
  • Fibronectins
  • Quinazolines
  • TGFB1 protein, human
  • Transforming Growth Factor beta1
  • Tyrphostins
  • RTKI cpd
  • Serum Albumin, Bovine
  • EGFR protein, human
  • ErbB Receptors
  • Amyloid Precursor Protein Secretases